Novo EVP says new data shows Wegovy stands out in obesity crowd
With sustained weight loss over a two-year period, Novo Nordisk's Wegovy has differentiated itself from existing competitors on the obesity drug market, says Novo Nordisk's EVP Martin Holst Lange. He also thinks the new results could help change the perception of obesity treatment.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
Novo Nordisk can celebrate obesity drug Wegovy, which is built on the GLP-1 analog semaglutide, as it has demonstrated a significant and sustained weight loss of 15.2 percent in a two-year study.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Wegovy weight loss results "very encouraging," says Novo EVP
For subscribers
Raising ambitions at Novo Nordisk an obvious move, says CEO
For subscribers
